Annie Yoshiyama Sells 9,586 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Annie Yoshiyama sold 9,586 shares of the business’s stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $2.31, for a total transaction of $22,143.66. Following the sale, the senior vice president owned 124,517 shares of the company’s stock, valued at approximately $287,634.27. The trade was a 7.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Annie Yoshiyama also recently made the following trade(s):

• On Monday, February 2nd, Annie Yoshiyama sold 4,167 shares of Allogene Therapeutics stock. The shares were sold at an average price of $1.72, for a total transaction of $7,167.24.

Allogene Therapeutics Stock Down 1.7%

ALLO stock traded down $0.04 during trading on Thursday, hitting $2.35. 9,371,892 shares of the company’s stock traded hands, compared to its average volume of 8,803,239. Allogene Therapeutics, Inc. has a 52 week low of $0.86 and a 52 week high of $4.46. The stock has a fifty day moving average price of $2.38 and a two-hundred day moving average price of $1.75. The stock has a market capitalization of $575.32 million, a price-to-earnings ratio of -2.70 and a beta of 0.53.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.08. As a group, equities research analysts expect that Allogene Therapeutics, Inc. will post -0.73 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on ALLO. Jefferies Financial Group upped their price target on shares of Allogene Therapeutics from $6.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Sanford C. Bernstein upped their price target on shares of Allogene Therapeutics from $1.60 to $3.85 and gave the stock a “market perform” rating in a research report on Tuesday, April 14th. Canaccord Genuity Group restated a “buy” rating and set a $14.00 price target on shares of Allogene Therapeutics in a research report on Friday, March 13th. Argus upped their price target on shares of Allogene Therapeutics from $1.60 to $3.85 and gave the stock a “market perform” rating in a research report on Tuesday, April 14th. Finally, Wall Street Zen upgraded shares of Allogene Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, February 22nd. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.44.

Institutional Investors Weigh In On Allogene Therapeutics

Several institutional investors have recently bought and sold shares of ALLO. AQR Capital Management LLC acquired a new stake in Allogene Therapeutics in the first quarter worth about $85,000. Goldman Sachs Group Inc. lifted its holdings in Allogene Therapeutics by 177.9% in the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock worth $8,547,000 after purchasing an additional 3,747,397 shares during the period. Jane Street Group LLC lifted its holdings in Allogene Therapeutics by 578.7% in the first quarter. Jane Street Group LLC now owns 1,116,681 shares of the company’s stock worth $1,630,000 after purchasing an additional 952,158 shares during the period. Geode Capital Management LLC lifted its holdings in Allogene Therapeutics by 13.0% in the second quarter. Geode Capital Management LLC now owns 3,794,827 shares of the company’s stock worth $4,289,000 after purchasing an additional 435,389 shares during the period. Finally, Rhumbline Advisers lifted its holdings in Allogene Therapeutics by 14.0% in the second quarter. Rhumbline Advisers now owns 209,336 shares of the company’s stock worth $237,000 after purchasing an additional 25,628 shares during the period. Institutional investors and hedge funds own 83.63% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.